Disc Medicine, Inc. $IRON Stock Position Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 18.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 194,725 shares of the company’s stock after buying an additional 29,653 shares during the period. Charles Schwab Investment Management Inc. owned about 0.56% of Disc Medicine worth $9,666,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IRON. Janus Henderson Group PLC lifted its position in Disc Medicine by 62.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after buying an additional 467,988 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Disc Medicine by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock valued at $88,421,000 after acquiring an additional 262,690 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Disc Medicine by 22.2% in the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company’s stock worth $64,782,000 after acquiring an additional 236,800 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Disc Medicine by 160.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 139,720 shares of the company’s stock valued at $8,856,000 after purchasing an additional 86,154 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. purchased a new stake in shares of Disc Medicine during the 4th quarter worth about $5,147,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $59.41 on Tuesday. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.11 and a current ratio of 32.11. The firm has a market cap of $2.07 billion, a P/E ratio of -13.29 and a beta of 0.77. The firm’s 50-day simple moving average is $57.01 and its 200-day simple moving average is $51.66.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.41). As a group, research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Activity

In other news, Director Kevin Bitterman sold 7,212 shares of Disc Medicine stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $60.99, for a total value of $439,859.88. Following the completion of the sale, the director directly owned 592,908 shares of the company’s stock, valued at approximately $36,161,458.92. This trade represents a 1.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jean M. Franchi sold 2,031 shares of the business’s stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $59.00, for a total transaction of $119,829.00. Following the sale, the chief financial officer directly owned 63,499 shares of the company’s stock, valued at approximately $3,746,441. This trade represents a 3.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 133,622 shares of company stock valued at $7,866,795 over the last three months. 3.64% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IRON. BMO Capital Markets lifted their price objective on shares of Disc Medicine from $112.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, May 12th. Morgan Stanley boosted their price objective on Disc Medicine from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, August 18th. Raymond James Financial initiated coverage on Disc Medicine in a report on Wednesday, June 11th. They issued a “strong-buy” rating and a $89.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Thursday, July 3rd. Finally, Truist Financial began coverage on Disc Medicine in a report on Monday, July 21st. They set a “buy” rating and a $86.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $98.30.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.